Last reviewed · How we verify
Continuous Infusion of ropivacaine 0.2%
Continuous Infusion of ropivacaine 0.2% is a Local anesthetic Small molecule drug developed by University of California, San Diego. It is currently FDA-approved for Local and regional anesthesia, Postoperative pain management via continuous peripheral nerve block infusion. Also known as: Perineural local anesthetic infusion.
Ropivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials and thereby producing local anesthesia.
Ropivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials and thereby producing local anesthesia. Used for Local and regional anesthesia, Postoperative pain management via continuous peripheral nerve block infusion.
At a glance
| Generic name | Continuous Infusion of ropivacaine 0.2% |
|---|---|
| Also known as | Perineural local anesthetic infusion |
| Sponsor | University of California, San Diego |
| Drug class | Local anesthetic |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Anesthesia/Pain Management |
| Phase | FDA-approved |
Mechanism of action
Ropivacaine reversibly binds to and blocks voltage-gated sodium channels on the inner surface of nerve cell membranes. This prevents sodium influx and depolarization, inhibiting the generation and conduction of nerve impulses. When administered as a continuous infusion, it provides sustained local anesthetic effect at the infusion site, commonly used for regional anesthesia and postoperative pain management.
Approved indications
- Local and regional anesthesia
- Postoperative pain management via continuous peripheral nerve block infusion
Common side effects
- Numbness or paresthesia at infusion site
- Systemic toxicity (CNS effects: dizziness, tinnitus, seizures)
- Cardiovascular effects (hypotension, arrhythmias) with systemic absorption
- Local tissue irritation or infection at catheter site
Key clinical trials
- Patient-Titrated Automated Intermittent Boluses of Local Anesthetic vs. a Continuous Infusion Via a Perineural Catheter for Postoperative Analgesia (PHASE4)
- Intrapleural Ropivacaine Infusion in Cardiac Surgery (PHASE4)
- TAP Blocks With Ropivacaine Continuous Infusion Catheters vs Single Dose Liposomal Bupivicaine After Kidney Transplant (PHASE4)
- Intravenous Lidocaine Plus Port-Site Ropivacaine for Recovery After Laparoscopic Surgery (PHASE3)
- Liposomal Bupivacaine vs Continuous Nerve Catheters for Below the Knee Amputations (PHASE4)
- Post Operative Infusion Pump Pain Study (PHASE4)
- Enhanced Recovery After Major Surgery and Chronic Pain for Total Knee Arthroplasty (NA)
- Randomized Study of an Analgesic Device Enabling Local Anesthetic Delivery and Neuromodulation After Shoulder/Foot Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Continuous Infusion of ropivacaine 0.2% CI brief — competitive landscape report
- Continuous Infusion of ropivacaine 0.2% updates RSS · CI watch RSS
- University of California, San Diego portfolio CI
Frequently asked questions about Continuous Infusion of ropivacaine 0.2%
What is Continuous Infusion of ropivacaine 0.2%?
How does Continuous Infusion of ropivacaine 0.2% work?
What is Continuous Infusion of ropivacaine 0.2% used for?
Who makes Continuous Infusion of ropivacaine 0.2%?
Is Continuous Infusion of ropivacaine 0.2% also known as anything else?
What drug class is Continuous Infusion of ropivacaine 0.2% in?
What development phase is Continuous Infusion of ropivacaine 0.2% in?
What are the side effects of Continuous Infusion of ropivacaine 0.2%?
What does Continuous Infusion of ropivacaine 0.2% target?
Related
- Drug class: All Local anesthetic drugs
- Target: All drugs targeting Voltage-gated sodium channels
- Manufacturer: University of California, San Diego — full pipeline
- Therapeutic area: All drugs in Anesthesia/Pain Management
- Indication: Drugs for Local and regional anesthesia
- Indication: Drugs for Postoperative pain management via continuous peripheral nerve block infusion
- Also known as: Perineural local anesthetic infusion
- Compare: Continuous Infusion of ropivacaine 0.2% vs similar drugs
- Pricing: Continuous Infusion of ropivacaine 0.2% cost, discount & access